David Mesher
Overview
Explore the profile of David Mesher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez A, Mesher D, Baena A, Salgado Y, Kasamatsu E, Cristaldo C, et al.
J Natl Cancer Inst
. 2024 Nov;
PMID: 39531343
Background: Cervical cytology is recommended by WHO as a triage option in HPV-based cervical cancer screening programmes. We assessed the performance of cytology to detect CIN3+ without and with knowledge...
2.
Checchi M, Mesher D, Panwar K, Anderson A, Beddows S, Soldan K
Vaccine
. 2023 Oct;
41(45):6734-6744.
PMID: 37821315
Introduction: The UK national human papillomavirus (HPV) vaccination programme was introduced in 2008 using the bivalent HPV16/18 vaccine, changing to the quadrivalent HPV6/11/16/18 vaccine from 2012. We provide an analysis...
3.
Padget M, Adam P, Dorfmuller M, Blondel C, Campos-Matos I, Fayad M, et al.
Euro Surveill
. 2023 Oct;
28(40).
PMID: 37796443
International comparisons of COVID-19 incidence rates have helped gain insights into the characteristics of the disease, benchmark disease impact, shape public health measures and inform potential travel restrictions and border...
4.
Baena A, Mesher D, Salgado Y, Martinez S, Villalba G, Amarilla M, et al.
Int J Cancer
. 2022 Dec;
152(8):1581-1592.
PMID: 36451311
VIA is recommended for triage of HPV-positive women attending cervical screening. In the multicentric ESTAMPA study, VIA performance for detection of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) among...
5.
Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H
Br J Cancer
. 2022 Mar;
127(2):278-287.
PMID: 35347326
Background: In England, bivalent vaccination (Cervarix) against high-risk human papillomavirus (HR-HPV) genotypes 16/18 was offered in a population-based catch-up campaign in 2008-2010 to girls aged 14-17 years. These women are...
6.
Mesher D, Thomas S, Linley E, Edmundson C, Checchi M, Waterboer T, et al.
Vaccine
. 2021 Jun;
39(30):4210-4218.
PMID: 34127297
Background: The National HPV Immunisation Programme was introduced in England in September 2008 using the HPV16/18 bivalent vaccine. We conducted serological surveillance to explore vaccination coverage levels. We also conducted...
7.
King E, Mesher D, Sonnenberg P, Linley E, Panwar K, Beddows S, et al.
Sex Transm Infect
. 2020 Dec;
97(5):382-386.
PMID: 33361466
Objectives: Men who have sex with men (MSM) have an increased risk of human papillomavirus (HPV) infection and related diseases compared with men who have sex exclusively with women. From...
8.
Nugent D, Stirrup O, Pett S, Panwar K, Checchi M, Mesher D, et al.
Sex Transm Infect
. 2020 Dec;
97(7):541-546.
PMID: 33328194
Objectives: Rectal swab specimens, either alone or pooled with first-void urine (FVU) and pharyngeal swab specimens, are used to test for (CT) and (NG) infection in men who have sex...
9.
Baena A, De Vuyst H, Mesher D, Kasubi M, Yuma S, Mwaiselage J, et al.
Cancer Epidemiol Biomarkers Prev
. 2020 Aug;
29(11):2261-2268.
PMID: 32856600
Background: To inform policy makers in Tanzania if and how best to implement rapid HPV testing, we assessed the interobserver reproducibility of HPV test at three different levels of the...
10.
Checchi M, Mesher D, Mohammed H, Soldan K
Sex Transm Infect
. 2019 Jul;
95(7):553.
PMID: 31320395
No abstract available.